about
Malignant gliomas: old and new systemic treatment approachesTargeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signalingThe future role of personalized medicine in the treatment of glioblastoma multiformeEORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies.Superoxide mediates direct current electric field-induced directional migration of glioma cells through the activation of AKT and ERK.Immunotherapy of brain cancers: the past, the present, and future directions.Inhibition of angiogenesis and invasion in malignant gliomas.CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways.Improving the prognosis for patients with glioblastoma: the rationale for targeting Src.LIN28 is involved in glioma carcinogenesis and predicts outcomes of glioblastoma multiforme patients.Changing the clinical picture of challenging tumors: tales becoming reality?Clinical trials in cellular immunotherapy for brain/CNS tumors.New therapies for recurrent glioblastomas.Small-Molecule Kinase-Inhibitors-Loaded Boron Cluster as Hybrid Agents for Glioma-Cell-Targeting Therapy.Overexpression of Golgi phosphoprotein-3 (GOLPH3) in glioblastoma multiforme is associated with worse prognosis.New developments in targeted molecular therapies for glioblastoma.Connexin 43 C-terminus directly inhibits the hyperphosphorylation of Akt/ERK through protein-protein interactions in glioblastoma
P2860
Q26744387-3A72B147-0513-4664-92A2-D77E55B6BCF0Q27011423-14E8D2B9-EC75-4A24-B0B4-6ACBBC583F89Q28391635-65DDC039-19C7-4042-BB76-A2B917C6C005Q33403967-E31593B2-2E70-420D-9C3A-1F2D42B722D2Q34132781-0794F115-6004-48B8-915F-DB593E2F04D2Q34684143-AD68A61F-5D32-4ED2-8DE0-FAE6AD1B2D47Q34701587-B63A54E2-65E1-4A34-8C09-F9202D9421E5Q37004664-E1DDD537-BC49-485E-8FDD-21C9E837EE93Q37330941-9EC57DDF-4B59-4835-8EE9-553CD0322A2AQ37479213-31B73D7E-C3B5-4904-B506-5AE329D9EA7CQ37514333-FBB71A14-540C-4AB9-B518-9A02BD07A9C3Q37575602-3AED89A5-4808-42C7-854D-B7C36BCD6004Q38094811-A7499D0D-72F2-49EE-8637-FC8D27A8ED98Q42415603-5F074FEA-5CF6-46CA-ACCF-176E5CD7CA61Q48292219-9087B9E8-D58F-416F-B507-7C36C7800A22Q48379843-0A60C528-569B-487E-9619-A7768B944E48Q55465496-3AC86A0C-4913-47B7-A416-8670C336F1D5Q58792718-C5E3E6A3-FCE3-45B4-AEB4-1E9C26062653
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Inhibiting kinases in malignant gliomas.
@ast
Inhibiting kinases in malignant gliomas.
@en
type
label
Inhibiting kinases in malignant gliomas.
@ast
Inhibiting kinases in malignant gliomas.
@en
prefLabel
Inhibiting kinases in malignant gliomas.
@ast
Inhibiting kinases in malignant gliomas.
@en
P2860
P1476
Inhibiting kinases in malignant gliomas.
@en
P2093
Andrew S Chi
Patrick Y Wen
P2860
P304
P356
10.1517/14728222.11.4.473
P407
P577
2007-04-01T00:00:00Z